WebDec 6, 2024 · Here, we highlight a handful of pulmonary fibrosis therapy candidates. 1. Pamrevlumab. One of the pathways drug developers have explored to treat IPF involves connective tissue growth factor (CTGF). The protein signals to cells to stimulate the development of fibrotic tissue In IPF. WebAug 25, 2009 · Connective tissue growth factor (CTGF) is a secreted protein that is strongly induced in human and experimental heart failure. CTGF is said to be profibrotic; however, the precise function of CTGF is unclear. We generated transgenic mice and rats with cardiomyocyte-specific CTGF overexpression (CTGF-TG). To investigate CTGF as …
The protein-protein interaction between connective tissue growth factor ...
WebJan 30, 2024 · The ability of CTGF to predict these end points remained after established cardiovascular risk factors were controlled for, including age, minority status, VADT treatment arm, history of CVD, history of hypertension, lipid levels, smoking status, use of ACE inhibitors, use of statins, and eGFR. WebOct 5, 2024 · CTGF: A potential therapeutic target for Bronchopulmonary dysplasia Bronchopulmonary dysplasia (BPD) is a chronic lung disease that often occurs in preterm infants. However, there is still no effective treatment for BPD. sharekhan.com customer care
Pamrevlumab for the treatment of idiopathic pulmonary fibrosis
WebJan 13, 2024 · Connective tissue growth factor (CTGF) is involved in the regulation of extracellular matrix (ECM) production. Elevated levels of CTGF can be found in plasma from patients with liver fibrosis and in experimental animal models of liver fibrosis, but the exact role of CTGF in, e.g., diet-induced human liver fibrosis is not entirely known. To address … WebCCN (for CYR61/ CTGF /NOV) proteins were identified originally from diverse cellular contexts and studied for their growth-promoting activities. It is now known that there are … WebFeb 17, 2024 · A fully recombinant human monoclonal antibody therapy has begun phase 3 assessment for the treatment of idiopathic pulmonary fibrosis (IPF). Pamrevlumab, a connective tissue growth factor (CTGF) inhibitor, is now being dosed in patients with IPF participating in the ZEPHYRUS-2 phase 3 trial. sharekhan.com app